Trade OXFORD BIOMEDICA PLC ORD 50P - OXB CFD

Add to favourite

1.983

7.95%

0.102

Low: 1.863

High: 2.02

Market Trading Hours* (UTC) Opens on Friday at 07:00

Mon - Fri: 07:00 - 15:30

Summary
Historical Data
Events
Income Statement
Balance Sheet

Trading сonditions

Spread

0.102

Long position overnight fee

-0.02529%

Short position overnight fee

0.003373%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

GBP

Margin

Stock exchange

United Kingdom of Great Britain and Northern Ireland

Commission on trade

*Information provided by Capital.com

Key Stats

Prev. Close*	1.837
Open*	1.863
1-Year Change*	-57.72%
Day's Range*	1.863 - 2.02
52 wk Range	1.64-5.75
Average Volume (10 days)	152.30K
Average Volume (3 months)	7.44M
Market Cap	174.83M
P/E Ratio	-100.00K
Shares Outstanding	96.80M
Revenue	119.02M
EPS	-0.64
Dividend (Yield %)	N/A
Beta	1.32
Next Earnings Date	Apr 23, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	1.983	0.120	6.44%	1.863	2.025	1.863
Apr 17, 2024	1.837	-0.048	-2.55%	1.885	1.923	1.837
Apr 16, 2024	1.909	-0.032	-1.65%	1.941	1.965	1.895
Apr 15, 2024	1.961	0.014	0.72%	1.947	2.005	1.919
Apr 12, 2024	1.989	-0.036	-1.78%	2.025	2.070	1.981
Apr 11, 2024	2.065	0.118	6.06%	1.947	2.070	1.947
Apr 10, 2024	1.977	0.030	1.54%	1.947	2.065	1.947
Apr 9, 2024	2.005	0.000	0.00%	2.005	2.030	1.967
Apr 8, 2024	2.005	0.000	0.00%	2.005	2.045	2.005
Apr 5, 2024	2.005	0.028	1.42%	1.977	2.015	1.943
Apr 4, 2024	1.977	0.008	0.41%	1.969	2.020	1.935
Apr 3, 2024	1.969	0.018	0.92%	1.951	1.975	1.865
Apr 2, 2024	1.951	-0.002	-0.10%	1.953	2.020	1.899
Mar 28, 2024	1.983	0.048	2.48%	1.935	2.010	1.903
Mar 27, 2024	1.961	0.064	3.37%	1.897	1.981	1.893
Mar 26, 2024	1.903	0.000	0.00%	1.903	1.945	1.849
Mar 25, 2024	1.903	0.026	1.39%	1.877	1.961	1.877
Mar 22, 2024	1.929	0.052	2.77%	1.877	1.973	1.877
Mar 21, 2024	1.907	0.012	0.63%	1.895	1.939	1.820
Mar 20, 2024	1.861	-0.002	-0.11%	1.863	1.927	1.828

OXFORD BIOMEDICA PLC ORD 50P Events

Time (UTC)	Country	Event
Monday, April 29, 2024
Time (UTC) 10:59	Country GB	Event Full Year 2023 Oxford Biomedica PLC Earnings Release Full Year 2023 Oxford Biomedica PLC Earnings Release Forecast - Previous -
Friday, June 21, 2024
Time (UTC) 14:00	Country GB	Event Oxford BioMedica PLC Annual Shareholders Meeting Oxford BioMedica PLC Annual Shareholders Meeting Forecast - Previous -
Wednesday, September 18, 2024
Time (UTC) 07:30	Country GB	Event Half Year 2024 Oxford Biomedica PLC Earnings Release Half Year 2024 Oxford Biomedica PLC Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	139.989	142.797	87.728	64.06	66.778
Revenue	139.989	142.797	87.728	64.06	66.778
Cost of Revenue, Total	70.808	60.157	41.655	35.723	22.763
Gross Profit	69.181	82.64	46.073	28.337	44.015
Total Operating Expense	170.209	122.029	93.422	78.527	52.863
Selling/General/Admin. Expenses, Total	28.223	15.152	11.262	11.881	7.433
Research & Development	60.937	40.189	29.749	22.546	29.689
Depreciation / Amortization					0.025
Interest Expense (Income) - Net Operating	0.051	0.165	0.831	1.883	-5.983
Other Operating Expenses, Total	31.579	6.366	9.925	6.494	-1.064
Operating Income	-30.22	20.768	-5.694	-14.467	13.915
Interest Income (Expense), Net Non-Operating	-15.69	-0.861	-0.84	-6.365	-8.893
Other, Net	-0.066	-0.027	-0.038	-0.057	-0.008
Net Income Before Taxes	-45.976	19.88	-6.572	-20.889	5.014
Net Income After Taxes	-45.159	19.011	-6.245	-16.066	7.541
Net Income Before Extra. Items	-39.157	19.011	-6.245	-16.066	7.541
Net Income	-39.157	19.011	-6.245	-16.066	7.541
Income Available to Common Excl. Extra. Items	-39.157	19.011	-6.245	-16.066	7.541
Income Available to Common Incl. Extra. Items	-39.157	19.011	-6.245	-16.066	7.541
Diluted Net Income	-39.157	19.011	-6.245	-16.066	7.541
Diluted Weighted Average Shares	94.8299	85.6351	79.9449	72.7099	69.2429
Diluted EPS Excluding Extraordinary Items	-0.41292	0.222	-0.07812	-0.22096	0.10891
Diluted Normalized EPS	-0.55953	0.222	-0.07812	-0.22096	0.10891
Dilution Adjustment				0	0
Unusual Expense (Income)	-21.389
Minority Interest	6.002
Dividends per Share - Common Stock Primary Issue	0

	Jun 2023	Dec 2022	Jun 2022	Dec 2021	Jun 2021
Total revenue	43.061	75.962	64.027	61.545	81.252
Revenue	43.061	75.962	64.027	61.545	81.252
Cost of Revenue, Total	21.122	42.909	27.899	21.785	38.372
Gross Profit	21.939	33.053	36.128	39.76	42.88
Total Operating Expense	93.809	87.025	83.184	60.435	61.594
Selling/General/Admin. Expenses, Total	12.838	11.744	16.479	9.143	6.009
Research & Development	31.417	33.627	27.31	25.481	14.708
Interest Expense (Income) - Net Operating	-0.008	0.013	0.038	0.166	-0.001
Other Operating Expenses, Total	28.912	20.121	11.458	3.86	2.506
Operating Income	-50.748	-11.063	-19.157	1.11	19.658
Interest Income (Expense), Net Non-Operating	-1.583	-7.463	-8.227	-0.392	-0.469
Other, Net	-0.013	-0.066		-0.055	0.028
Net Income Before Taxes	-52.344	-18.592	-27.384	0.663	19.217
Net Income After Taxes	-52.661	-17.525	-27.634	0.942	18.069
Net Income Before Extra. Items	-47.956	-13.674	-25.483	0.942	18.069
Net Income	-47.956	-13.674	-25.483	0.942	18.069
Income Available to Common Excl. Extra. Items	-47.956	-13.674	-25.483	0.942	18.069
Income Available to Common Incl. Extra. Items	-47.956	-13.674	-25.483	0.942	18.069
Diluted Net Income	-47.956	-13.674	-25.483	0.942	18.069
Diluted Weighted Average Shares	96.5212	96.2885	93.3713	86.6704	84.5999
Diluted EPS Excluding Extraordinary Items	-0.49684	-0.14201	-0.27292	0.01087	0.21358
Dividends per Share - Common Stock Primary Issue	0	0	0		0
Diluted Normalized EPS	-0.50002	-0.2864	-0.27292	0.01087	0.21358
Minority Interest	4.705	3.851	2.151
Unusual Expense (Income)	-0.472	-21.389

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	215.504	163.844	107.946	56.937	65.926
Cash and Short Term Investments	141.285	108.944	46.743	16.243	32.244
Cash & Equivalents
Total Receivables, Net	57.595	42.095	51.423	33.623	28.591
Accounts Receivable - Trade, Net	45.006	35.945	43.722	26.172	24.294
Total Inventory	12.625	9.521	6.912	2.579	4.251
Prepaid Expenses	3.976	3.21	2.629	1.773	0.84
Total Assets	460.18	237.229	183.928	122.928	112.4
Property/Plant/Equipment, Total - Net	133.78	69.728	72.304	61.932	31.791
Property/Plant/Equipment, Total - Gross	188.238	112.133	102.274	82.304	46.443
Accumulated Depreciation, Total	-54.458	-42.405	-29.97	-20.372	-14.652
Intangibles, Net	105.225	0.052	0.073	0.095	0.117
Long Term Investments				0	10.966
Total Current Liabilities	59.663	33.307	52.455	28.941	28.506
Accounts Payable	13.604	5.26	7.777	7.311	3.746
Accrued Expenses	22.975	13.798	11.939	6.986	7.676
Notes Payable/Short Term Debt	0	0	0	0	0
Other Current Liabilities, Total	19.789	13.396	28.264	14.162	17.084
Total Liabilities	255.527	49.891	71.182	47.298	77.659
Total Long Term Debt	110.986	8.488	9.37	7.907	41.153
Long Term Debt	39.78			0	41.153
Other Liabilities, Total	47.751	8.096	9.357	10.091	7.721
Total Equity	204.653	187.338	112.746	75.63	34.741
Common Stock	48.132	43.088	41.161	38.416	33.034
Additional Paid-In Capital	379.953	307.765	258.017	222.618	172.074
Retained Earnings (Accumulated Deficit)	-223.432	-163.515	-186.432	-185.404	-170.367
Total Liabilities & Shareholders’ Equity	460.18	237.229	183.928	122.928	112.4
Total Common Shares Outstanding	96.2632	86.1751	82.3206	76.8591	66.1035
Cash	141.285	108.944	46.743	16.243	32.244
Other Current Assets, Total	0.023	0.074	0.239	2.719	0
Note Receivable - Long Term	5.01	3.605	3.605	3.605	3.6
Current Port. of LT Debt/Capital Leases	3.295	0.853	4.475	0.482	0
Capital Lease Obligations	71.206	8.488	9.37	7.907	0
Deferred Income Tax	5.588		0	0.359	0.279
Other Long Term Assets, Total			0	0.359
Goodwill, Net	0.661
Minority Interest	31.539

	Jun 2023	Dec 2022	Jun 2022	Dec 2021	Jun 2021
Total Current Assets	177.696	215.504	202.909	163.844	123.911
Cash and Short Term Investments	129.43	141.285	118.51	108.944	61.275
Cash	129.43	141.285	118.51	108.944	61.275
Total Receivables, Net	29.533	57.595	66.568	42.095	51.043
Accounts Receivable - Trade, Net	20.522	45.006	56.515	35.945	43.323
Total Inventory	13.542	12.625	13.853	9.521	8.466
Prepaid Expenses	5.16	3.976	3.942	3.21	2.887
Other Current Assets, Total	0.031	0.023	0.036	0.074	0.24
Total Assets	401.065	460.18	466.699	237.229	197.686
Property/Plant/Equipment, Total - Net	120.554	133.78	136.266	69.728	70.127
Property/Plant/Equipment, Total - Gross	178.805	188.238	187.537	112.133	106.134
Accumulated Depreciation, Total	-58.251	-54.458	-51.271	-42.405	-36.007
Intangibles, Net	97.251	105.225	108.415	0.052	0.063
Note Receivable - Long Term	4.931	5.01	3.605	3.605	3.585
Total Current Liabilities	53.53	59.663	110.813	33.307	47.255
Accounts Payable	9.234	13.604	9.487	5.26	10.254
Accrued Expenses	16.974	22.975	16.796	13.798	13.036
Notes Payable/Short Term Debt	0	0	68.405	0	0
Current Port. of LT Debt/Capital Leases	3.666	3.295	2.046	0.853	0.818
Other Current Liabilities, Total	23.656	19.789	14.079	13.396	23.147
Total Liabilities	228.956	255.527	244.667	49.891	65.082
Total Long Term Debt	109.483	110.986	37.046	8.488	8.915
Capital Lease Obligations	71.047	71.206	37.046	8.488	8.915
Other Liabilities, Total	34.856	47.751	51.643	8.096	8.912
Total Equity	172.109	204.653	222.032	187.338	132.604
Common Stock	48.26	48.132	48.038	43.088	41.307
Additional Paid-In Capital	380.247	379.953	379.95	307.765	258.474
Retained Earnings (Accumulated Deficit)	-256.398	-223.432	-205.956	-163.515	-167.177
Total Liabilities & Shareholders’ Equity	401.065	460.18	466.699	237.229	197.686
Total Common Shares Outstanding	96.5212	96.2632	86.1751	86.1751	82.5918
Goodwill, Net	0.633	0.661	15.504
Deferred Income Tax	5.04	5.588	7.183
Minority Interest	26.047	31.539	37.982
Long Term Debt	38.436	39.78

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Oxford BioMedica plc Company profile

About Oxford BioMedica plc

Oxford BioMedica Plc is a United Kingdom-based gene and cell therapy company. The Company and its subsidiaries have developed lentiviral vector delivery system, LentiVector platform, which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, central nervous system (CNS) disorders and liver diseases. The Company's product pipeline includes OXB-302, OXB-203, OXB-204 and OXB-103 and OXB-401. The Company has also developed partnership with various pharmaceutical companies to develop potential gene and cell therapy products. Its partnered products include AXO-LENTI-PD, SAR 422459 and SAR421869.

Financial summary

BRIEF: For the six months ended 30 June 2021, Oxford BioMedica plc revenues increased from £34M to £81.3M. Net income totaled £18.1M vs. loss of £6.7M. Revenues reflect Europe segment increase from £19M to £70.3M. Net Income reflects Platform segment income totaling £24.4M vs. loss of £3.1M. Basic Earnings per Share excluding Extraordinary Items increased from -£0.09 to £0.22.

Equity composition

10/2003, Rights Issue, 27 new shs for every 50 shs held @ GBP 0.17 (Fct:1.54). 03/2001, Rights Issue, 1 new share for every 9 shs held @ GBP 0.55 (Fct:1.111111). 03/1998, Rights Issue, 1 new share for every 4 shs held @ GBP 0.10 (Fct:1.076). 05/2014, Priority Issue, 1 new shares for every 5 shares held @ GBp 2 (Factor:1).

Industry:

Bio Therapeutic Drugs

Windrush Court
Transport Way
OXFORD
OXFORDSHIRE OX4 6LT
GB

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024